October 22, 2026 |
1 min read |
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Watch on YouTube
In this episode of Denatured, you’ll listen to Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We explore why kidney disease has historically been a difficult target for cell and gene therapies, and how advances in delivery, therapeutic modalities and evolving regulatory frameworks are shaping the path to commercially viable treatments.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Bruce Culleton, CEO, ProKidney
Demetri Maxim, CEO, Nephrogen
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.
The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.